Figure 3.

Idd9 congenic mice retain diabetes protection in the presence of NOD-derived bone marrow, yet no evidence of immune regulation. (A) Diabetes incidence in NODScid recipients following adoptive transfer of 20 million splenocytes from 13 week old NOD (n = 6) and Idd9 congenic (n = 4) mice, or co-transfer of 10 million NOD plus 10 million Idd9 congenic splenocytes (n = 6) determined by weekly blood glucose monitoring. The results are representative of 2 experiments. (B) Blood glucose levels measured weekly from 15 weeks of age in female NOD (n = 23), NOD.IL4KO (n = 27), Idd9 congenic (n = 33), and Idd9.IL4KO (n = 29) mice until 33 weeks of age to determine diabetes incidence. In (C), diabetes incidence is shown for lethally irradiated (950 Rad) Idd9 congenic and NOD mice reconstituted with bone marrow cells (10 million) from 5 week old NOD donors. Results representative of 2 independent experiments. In (D) bone marrow cells (10 million) from NOD.NONThy1.1 donors were injected as in (C). Islet-infiltrating cells were isolated from recipients 6 weeks following transfer and the % donor (Thy1.1+) CD4 and CD8 T cells determined by flow cytometry.